Using the science of ARS to transform the next generation of drug discovery
At ZYMEDI we are putting our extensive knowledge of aminoacyl-tRNA synthetase (ARS) science to work to transform the next generation of drug discovery.
Focused on the most challenging inflammatory diseases and various refractory cancers, our pipeline has unlimited potential. It includes first-in-class treatments for pulmonary arterial hypertension (PAH), nonalcoholic steatohepatitis (NASH), and a pan-KRAS inhibitor that targets AIMP2-DX2 for KRAS-mutated cancers followed by additional target and lead platforms.